RTS,S
Sign in to savethumb|A poster advertising trials of the RTS,S vaccine RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M). , the vaccine has been given to 1million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. 18 million doses have been allocated for 2023–2025. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital ad
Key facts
- Drug.type
- vaccine
- Drug.target
- P. falciparum; to a lesser extent Hepatitis B
- Drug.vaccine_type
- protein subunit
- Drug.tradename
- Mosquirix
- Drug.legal_status
- Rx-only
- Drug.routes_of_administration
- intramuscular injection (0.5 mL)
- Drug.CAS_number
- 149121-47-1
- Drug.UNII
- 69SE2D63CL
via Wikipedia infobox
Article
6 sectionsContents
- Medical uses
- History
- Components and mechanism
- References
- Further reading
- External links
thumb|A poster advertising trials of the RTS,S vaccine RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M). , the vaccine has been given to 1million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. 18 million doses have been allocated for 2023–2025. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30% and reduces toddler deaths by 15%.
== Medical uses ==